• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

伊曲康唑对具有降低唑类药物敏感性的新型真菌病原体 Lentulus aspergillus、Neosartorya udagawae 和 Cryptococcus gattii 的活性。

Isavuconazole activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibility.

机构信息

Johns Hopkins School of Medicine, Baltimore, Maryland, USA.

出版信息

J Clin Microbiol. 2013 Sep;51(9):3090-3. doi: 10.1128/JCM.01190-13. Epub 2013 Jun 26.

DOI:10.1128/JCM.01190-13
PMID:23804388
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3754638/
Abstract

Isavuconazole is an extended-spectrum triazole with in vitro activity against a wide variety of fungal pathogens. Clinical isolates of molds Aspergillus lentulus and Neosartorya udagawae and yeast Cryptococcus gattii VGII (implicated in the outbreak in the Pacific Northwest, North America) exhibit reduced susceptibilities to several azoles but higher susceptibilities to isavuconazole.

摘要

伊曲康唑是一种具有广泛体外活性的三唑类药物，可对抗多种真菌病原体。曲霉菌 Aspergillus lentulus 和 Neosartorya udagawae 的临床分离株和酵母 Cryptococcus gattii VGII（与北美太平洋西北地区的疫情有关）对几种唑类药物的敏感性降低，但对伊曲康唑的敏感性更高。

相似文献

1
Isavuconazole activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibility.伊曲康唑对具有降低唑类药物敏感性的新型真菌病原体 Lentulus aspergillus、Neosartorya udagawae 和 Cryptococcus gattii 的活性。
J Clin Microbiol. 2013 Sep;51(9):3090-3. doi: 10.1128/JCM.01190-13. Epub 2013 Jun 26.
2
Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method.采用CLSI M27 - A3肉汤微量稀释法对新生隐球菌-格特隐球菌复合种的异氟康唑MIC分布及流行病学截断值进行多中心研究。
Antimicrob Agents Chemother. 2015 Jan;59(1):666-8. doi: 10.1128/AAC.04055-14. Epub 2014 Oct 13.
3
In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan.日本 140 株参考真菌株和 165 株临床分离酵母菌的体外异康唑活性。
Int J Antimicrob Agents. 2010 Oct;36(4):324-31. doi: 10.1016/j.ijantimicag.2010.06.003. Epub 2010 Jul 31.
4
Activity of Isavuconazole against Opportunistic Fungal Pathogens from Two Mycology Reference Laboratories.伊曲康唑对两个真菌学参考实验室的机会性真菌病原体的活性。
Antimicrob Agents Chemother. 2018 Sep 24;62(10). doi: 10.1128/AAC.01230-18. Print 2018 Oct.
5
In vitro activity of isavuconazole versus opportunistic filamentous fungal pathogens from the SENTRY Antifungal Surveillance Program, 2017-2018.2017-2018 年 SENTRY 抗真菌监测计划中，伊曲康唑与机会性丝状真菌病原体的体外活性。
Diagn Microbiol Infect Dis. 2020 May;97(1):115007. doi: 10.1016/j.diagmicrobio.2020.115007. Epub 2020 Jan 29.
6
Isavuconazole: A new broad-spectrum azole. Part 1: In vitro activity.伊曲康唑：一种新型广谱唑类药物。第 1 部分：体外活性。
J Mycol Med. 2018 Mar;28(1):8-14. doi: 10.1016/j.mycmed.2018.02.005. Epub 2018 Mar 11.
7
Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values.2013年收集的常见和罕见机会性真菌对艾沙康唑、米卡芬净及8种对照抗真菌药物的敏感性概况：使用临床和实验室标准协会（CLSI）特定菌种临床断点及建议的流行病学截断值对抗真菌药物耐药性进行的时间分析
Diagn Microbiol Infect Dis. 2015 Aug;82(4):303-13. doi: 10.1016/j.diagmicrobio.2015.04.008. Epub 2015 Apr 29.
8
Evaluation of isavuconazole MIC strips for susceptibility testing of Aspergillus and Scedosporium species.用于曲霉属和赛多孢属菌种药敏试验的艾沙康唑MIC试纸条评估。
Med Mycol. 2019 Jun 1;57(4):429-433. doi: 10.1093/mmy/myy071.
9
In vitro antifungal susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 350 clinical, veterinary, and environmental Cryptococcus gattii isolates.对全球范围内 350 株临床、兽医和环境分离的隐球菌的体外抗真菌药敏试验和扩增片段长度多态性基因分型研究。
Antimicrob Agents Chemother. 2010 Dec;54(12):5139-45. doi: 10.1128/AAC.00746-10. Epub 2010 Sep 20.
10
In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.新型唑类药物艾沙康唑（BAL4815）与其他六种抗真菌药物对来自古巴的162株新型隐球菌分离株的体外活性比较
Antimicrob Agents Chemother. 2008 Apr;52(4):1580-2. doi: 10.1128/AAC.01384-07. Epub 2008 Jan 22.

引用本文的文献

1
Comparison of Morphological, Virulence, and Antifungal Susceptibility Characteristics Within .. 内形态学、毒力和抗真菌药敏特性的比较
Infect Drug Resist. 2025 Jul 30;18:3761-3769. doi: 10.2147/IDR.S532973. eCollection 2025.
2
Clinical research advances of isavuconazole in the treatment of invasive fungal diseases.伊曲康唑治疗侵袭性真菌病的临床研究进展。
Front Cell Infect Microbiol. 2022 Dec 1;12:1049959. doi: 10.3389/fcimb.2022.1049959. eCollection 2022.
3
New Antifungal Agents with Azole Moieties.含唑类基团的新型抗真菌药物
Pharmaceuticals (Basel). 2022 Nov 17;15(11):1427. doi: 10.3390/ph15111427.
4
A Fatal Fungal Infection: (VGI) Meningitis in Texas.一例致命真菌感染：德克萨斯州的（VGI）脑膜炎
Open Forum Infect Dis. 2022 May 9;9(7):ofac236. doi: 10.1093/ofid/ofac236. eCollection 2022 Jul.
5
Antifungal Resistance and the Role of New Therapeutic Agents.抗真菌耐药性与新型治疗药物的作用
Curr Infect Dis Rep. 2022;24(9):105-116. doi: 10.1007/s11908-022-00782-5. Epub 2022 Jul 5.
6
An Under-recognized Cause of Antifungal Drug-Resistant Aspergillosis.一种未被充分认识的耐抗真菌药曲霉病病因。
Open Forum Infect Dis. 2021 Aug 29;8(8):ofab392. doi: 10.1093/ofid/ofab392. eCollection 2021 Aug.
7
Isavuconazole: Mechanism of Action, Clinical Efficacy, and Resistance.艾沙康唑：作用机制、临床疗效及耐药性
J Fungi (Basel). 2020 Nov 29;6(4):324. doi: 10.3390/jof6040324.
8
Clinical and Microbiological Characterization of Invasive Pulmonary Aspergillosis Caused by in China.中国由[具体病原体未给出]引起的侵袭性肺曲霉病的临床和微生物学特征
Front Microbiol. 2020 Jul 28;11:1672. doi: 10.3389/fmicb.2020.01672. eCollection 2020.
9
Treatment Failure of Isavuconazole in a Patient with Cryptococcosis.伏立康唑治疗隐球菌病患者失败。
Mycopathologia. 2019 Oct;184(5):667-670. doi: 10.1007/s11046-019-00374-3. Epub 2019 Aug 26.
10
Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy.聚焦于艾沙康唑治疗侵袭性曲霉病和毛霉病：设计、研发及在治疗中的地位
Drug Des Devel Ther. 2018 Apr 30;12:1033-1044. doi: 10.2147/DDDT.S145545. eCollection 2018.

本文引用的文献

1
Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method.多中心研究伊曲康唑 MIC 分布和曲霉属的 CLSI M38-A2 肉汤微量稀释法的流行病学截断值。
Antimicrob Agents Chemother. 2013 Aug;57(8):3823-8. doi: 10.1128/AAC.00636-13. Epub 2013 May 28.
2
The cdr1B efflux transporter is associated with non-cyp51a-mediated itraconazole resistance in Aspergillus fumigatus.cdr1B 外排转运蛋白与烟曲霉中非 Cyp51a 介导的伊曲康唑耐药性相关。
J Antimicrob Chemother. 2013 Jul;68(7):1486-96. doi: 10.1093/jac/dkt075. Epub 2013 Apr 10.
3
Autochthonous and dormant Cryptococcus gattii infections in Europe.欧洲本土和休眠的新型隐球菌感染。
Emerg Infect Dis. 2012 Oct;18(10):1618-24. doi: 10.3201/eid1810.120068.
4
Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.新型隐球菌-格特隐球菌种复合体：氟康唑、伊曲康唑、泊沙康唑和伏立康唑野生型药敏终点分布和流行病学折点的国际研究。
Antimicrob Agents Chemother. 2012 Nov;56(11):5898-906. doi: 10.1128/AAC.01115-12. Epub 2012 Sep 4.
5
Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections.评估伊曲康唑治疗侵袭性真菌感染的药代动力学和临床实用性。
Expert Opin Drug Metab Toxicol. 2012 Jun;8(6):759-65. doi: 10.1517/17425255.2012.683859. Epub 2012 Apr 25.
6
Epidemiologic cutoff values for triazole drugs in Cryptococcus gattii: correlation of molecular type and in vitro susceptibility.隐球菌中三唑类药物的流行病学截断值：分子类型与体外药敏的相关性。
Diagn Microbiol Infect Dis. 2012 Jun;73(2):144-8. doi: 10.1016/j.diagmicrobio.2012.02.018. Epub 2012 Apr 10.
7
Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India.在印度从携带 cyp51A 基因 TR/L98H 突变的多唑耐药烟曲霉分离株。
J Antimicrob Chemother. 2012 Feb;67(2):362-6. doi: 10.1093/jac/dkr443. Epub 2011 Oct 25.
8
Role of Aspergillus lentulus 14-α sterol demethylase (Cyp51A) in azole drug susceptibility.阿萨希毛霉 14-α 甾醇去甲基酶（Cyp51A）在唑类药物敏感性中的作用。
Antimicrob Agents Chemother. 2011 Dec;55(12):5459-68. doi: 10.1128/AAC.05178-11. Epub 2011 Sep 26.
9
Cryptococcus gattii: a resurgent fungal pathogen.新型隐球菌：一种死灰复燃的真菌病原体。
Trends Microbiol. 2011 Nov;19(11):564-71. doi: 10.1016/j.tim.2011.07.010. Epub 2011 Aug 29.
10
Cryptococcus gattii: an emerging fungal pathogen infecting humans and animals.新型隐球菌：一种感染人类和动物的新兴真菌病原体。
Microbes Infect. 2011 Oct;13(11):895-907. doi: 10.1016/j.micinf.2011.05.009. Epub 2011 Jun 1.